Miro Venturi

With offices in Europe, North America and APAC, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to healthcare businesses. Prioritized areas of focus include Biopharma Products, Consumer Health, Animal & Environmental Health, Healthcare IT, Diagnostics, Life Science Tools & Biologic Services, MedTech, and Pharma Services. ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. ARCHIMED manages €9 billion across its various funds, including the largest healthcare-only private equity fund raised by a European-based General Partner. Since inception, ARCHIMED has been a committed Impact investor, both directly and through its EURÊKA Foundation.

We are a Swiss digital company specializing in AI-powered diagnostic tools for Alzheimers Disease. Our innovative approach leverages a unique epigenetic biomarker found in plasma, allowing Tivenix to successfully identify an Alzheimers fingerprint within cell-free DNA through our proprietary machine learning platform.

At Tethis we aim to make liquid biopsy a standard, reproducible, oncology diagnostic. Our proprietary slides allow immediate, fully automated and gentle processing of blood samples, three unaddressed elements that are crucial to ensure standardization and to maintain clinical informativity. High throughput analytical protocols are then performed for highly sensitive and specific blood-based cancer testing in different clinical settings.

With offices in Europe, North America and APAC, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to healthcare businesses. Prioritized areas of focus include Biopharma Products, Consumer Health, Animal & Environmental Health, Healthcare IT, Diagnostics, Life Science Tools & Biologic Services, MedTech, and Pharma Services. ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. ARCHIMED manages €9 billion across its various funds, including the largest healthcare-only private equity fund raised by a European-based General Partner. Since inception, ARCHIMED has been a committed Impact investor, both directly and through its EURÊKA Foundation.

We are a Swiss digital company specializing in AI-powered diagnostic tools for Alzheimers Disease. Our innovative approach leverages a unique epigenetic biomarker found in plasma, allowing Tivenix to successfully identify an Alzheimers fingerprint within cell-free DNA through our proprietary machine learning platform.

Sintetica is a swiss pharmaceutical company established in 1921. We are fully committed to innovate therapies and drugs in anaesthesia, pain management, intensive care and neuromodulation.

At Tethis we aim to make liquid biopsy a standard, reproducible, oncology diagnostic. Our proprietary slides allow immediate, fully automated and gentle processing of blood samples, three unaddressed elements that are crucial to ensure standardization and to maintain clinical informativity. High throughput analytical protocols are then performed for highly sensitive and specific blood-based cancer testing in different clinical settings.